Class II · Moderate risk
oxyTOCIN 15 units added to Lactated Ringer's 250 mL
Lack of assurance of sterility. Validation data for decontamination cycles is lacking.
FDA drug recalls in 2023
Every FDA drug recall initiated in 2023, newest first, with its risk class, status and the reason the FDA recorded. Use the cause and risk filters to narrow the year down.
1,122 recalls, newest first.
Class II · Moderate risk
heparin 2500 units added to 0.9% sodium chloride 250mL
Lack of assurance of sterility. Validation data for decontamination cycles is lacking.
Class II · Moderate risk
oxyTOCIN 15 units added to 0.9% sodium chloride 250 mL
Lack of assurance of sterility. Validation data for decontamination cycles is lacking.
Class II · Moderate risk
oxyTOCIN 10 units added to Lactated Ringer's 500 mL
Lack of assurance of sterility. Validation data for decontamination cycles is lacking.
Class II · Moderate risk
vancomycin 750 mg/250 mL added to 0.9% Sodium Chloride
Lack of assurance of sterility. Validation data for decontamination cycles is lacking.
Class II · Moderate risk
vancomycin 2 g/500 mL added to 0.9% Sodium Chloride
Lack of assurance of sterility. Validation data for decontamination cycles is lacking.
Class II · Moderate risk
vancomycin 1.75g added to 0.9% sodium chloride 500mL
Lack of assurance of sterility. Validation data for decontamination cycles is lacking.
Class II · Moderate risk
vancomycin 1.5 g/250mL added to 5% dextrose
Lack of assurance of sterility. Validation data for decontamination cycles is lacking.
Class II · Moderate risk
vancomycin 1.5 g/500 mL added to 0.9% sodium chloride
Lack of assurance of sterility. Validation data for decontamination cycles is lacking.
Class II · Moderate risk
vancomycin 1.5 g/250 mL added to 0.9% sodium chloride
Lack of assurance of sterility. Validation data for decontamination cycles is lacking.
Class II · Moderate risk
PHENYLephrine 1
Lack of assurance of sterility. Validation data for decontamination cycles is lacking.
Class II · Moderate risk
phenylephrine 50 mg added to 0.9% sodium chloride 250mL
Lack of assurance of sterility. Validation data for decontamination cycles is lacking.
Class II · Moderate risk
PHENYLephrine
Lack of assurance of sterility. Validation data for decontamination cycles is lacking.
Class II · Moderate risk
phenylephrine
Lack of assurance of sterility. Validation data for decontamination cycles is lacking.
Class II · Moderate risk
PHENYLephrine 20mg/250ml added to 0.9% sodium chloride
Lack of assurance of sterility. Validation data for decontamination cycles is lacking.
Class II · Moderate risk
PHENYLephrine
Lack of assurance of sterility. Validation data for decontamination cycles is lacking.
Class II · Moderate risk
EPINEPHrine 8mg/250ml added to dextrose 5%
Lack of assurance of sterility. Validation data for decontamination cycles is lacking.
Class II · Moderate risk
EPINEPHrine added to dextrose 5%
Lack of assurance of sterility. Validation data for decontamination cycles is lacking.
Class II · Moderate risk
EPINEPHrine
Lack of assurance of sterility. Validation data for decontamination cycles is lacking.
Class II · Moderate risk
Cardioplegia Solution del Nido Formula
Lack of assurance of sterility. Validation data for decontamination cycles is lacking.
Class II · Moderate risk
vancomycin 1.25 g/250 mL added to 0.9% Sodium Chloride
Lack of assurance of sterility. Validation data for decontamination cycles is lacking.
Class II · Moderate risk
EPINEPHrine 4mg/250mL added to 0.9% sodium chloride
Lack of assurance of sterility. Validation data for decontamination cycles is lacking.
Class II · Moderate risk
dilTIAZem 125mg/125mL
Lack of assurance of sterility. Validation data for decontamination cycles is lacking.
Class II · Moderate risk
glycopyrrolate 1 mg/5 mL
Lack of assurance of sterility. Validation data for decontamination cycles is lacking.
Class II · Moderate risk
dilTIAZem 125mg/125mL
Lack of assurance of sterility. Validation data for decontamination cycles is lacking.